首頁 > 市場調查報告書 > 醫療設備

醫學影像診斷核子醫學

市場調查報告書

商品編碼

1736635

2026 年至 2032 年核醫市場類型、應用、最終用戶和地區分析

Nuclear Medicine Market By Type, Application End-Users, Region for 2026-2032

出版日期: 2025年05月05日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

核子醫學市場評估（2026-2032）

心血管疾病、癌症、呼吸道疾病、神經系統疾病、代謝性疾病等慢性疾病的盛行率不斷上升，是核醫市場發展的關鍵促進因素。因此，慢性疾病盛行率的上升將推動市場規模的成長，到2024年將突破68億美元，到2032年將達到129.9億美元的估值。

與傳統醫藥相比，核子醫學在醫療保健領域的應用尚處於起步階段。然而，醫學影像處理技術、放射性藥物的進步以及人們對核醫學益處的日益深入理解，正在推動核醫學的應用。因此，核子醫學在醫療保健領域的日益普及將推動市場在2026年至2032年間以9.30%的複合年成長率成長。

核子醫學市場定義/概述

核子醫學是一個跨學科領域，利用放射性物質或放射性藥物來診斷和治療各種疾病，包括神經病學、循環系統、內分泌系統疾病、消化器官系統疾病和癌症。放射性藥物含有放射性示蹤劑，注射到病人體內後會發射伽瑪射線。這些輻射可被單光子發射電腦斷層掃描 (SPECT) 和正子斷層掃描 (PET) 等先進成像技術捕獲，從而產生超越傳統成像方法的高精度影像，有助於疾病的早期發現、準確診斷和全面檢測。

放射性藥物的最新進展提高了我們研究微觀生理過程的能力，例如癌細胞增殖、心臟病中的心肌灌注、重症肺炎中的通氣以及甲狀腺功能亢進症中的甲狀腺和副甲狀腺活動。核子醫學在下一代療法的研發中得到越來越廣泛的應用，包括放射性藥物與抗體、生物藥品和胜肽的結合物。這使得標靶藥物傳遞、劑量最佳化和創新治療方案的開發成為可能。因此，核子醫學不僅是一種強大的診斷工具，而且在推動各個醫學學科的治療策略方面也發揮關鍵作用。

癌症和心血管疾病的日益普及將如何推動核醫市場的成長？

根據世界衛生組織 (WHO) 的數據，癌症是全球首要的死亡原因，2020 年約有 1,000 萬人死於癌症。根據美國心臟協會的報告，心血管疾病是全球首要的死亡原因，2019 年每年導致超過 1,790 萬人死亡。放射性藥物和診斷影像設備的技術進步根據 Verified Market Research 的調查，放射性藥物市場預計在 2023 年價值 60.5 億美元，到 2032 年將達到 136.1 億美元，複合年成長率為 11.76%。

核子醫學研發投入不斷增加。美國能源局2021 財政年度用於核子物理研究的預算為 7.13 億美元。歐盟委員會在歐洲原子能共同體 2021-2025 年研究與培訓計畫下為核子研究和培訓活動撥款 13.8 億歐元。個人化醫療的認知度和接受度不斷提高根據 Verified Market Research 的報告，個人化醫療市場預計將在 2023 年成長到 1302.3 億美元，2032 年成長到 2725.9 億美元，2026 年至 2032 年的複合年成長率為 10.67%。根據個人化醫療聯盟的調查，73% 的腫瘤科醫師為癌症患者使用個人化醫療檢測。

放射性同位素在分子影像上的應用正在不斷擴大。根據美國美國核能管理委員會的報告，美國每年進行約5,000萬次核醫檢查。老年人口的增加以及隨之而來的慢性病的增加是主要促進因素。聯合國報告稱，全球65歲及以上人口的成長速度超過所有其他年齡段，預計到2050年將加倍，達到15億。世界衛生組織預測，到2030年，世界上六分之一的人將年齡在60歲或以上，這將增加對診斷和治療核醫程序的需求。

核子醫學程序和設備的高成本將如何阻礙核醫市場的成長？

核子醫學檢測和設備的高昂成本阻礙了核子醫學市場的成長。根據美國放射學會的數據，在美國，PET/ 電腦斷層掃描的平均費用為1,250至1,650美元，對許多患者來說過於昂貴。此外，監管要求也十分嚴格。美國美國核能管理委員會報告稱，審查和核准一種新的放射性藥物平均需要24個月。在歐洲，歐洲藥品管理局（EMA）在2018年至2022年期間僅核准了三種新的放射性藥物，凸顯了核准流程的嚴謹性。

核子醫學和分子影像學會指出，Technetium-99m 等常用放射性同位素的半衰期僅為 6 小時，這增加了物流的複雜性並增加了成本。《核子醫學雜誌》發表的一項研究表明，半衰期較短的放射性藥物可能由於物流方面的挑戰而導致高達 20% 的製備劑量無法使用。此外，熟練的核子醫學技術人員也存在短缺。美國勞工統計局預測，從 2019 年到 2029 年，對核醫技術人員的需求將增加 5%，但同時也指出，該領域規模較小，2019 年僅約有 18,000 個職缺。美國放射技術員學院的一項調查發現，2019 年核醫技術人員職缺率為 4.7%，顯示合格人員短缺。

概述
北美洲
- 美國
- 加拿大
- 墨西哥
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 其他歐洲國家
亞太地區
- 中國
- 日本
- 印度
- 其他亞太地區
拉丁美洲
- 巴西
- 阿根廷
- 其他拉丁美洲
中東和非洲
- 阿拉伯聯合大公國
- 沙烏地阿拉伯
- 南非
- 其他中東和非洲地區

第9章競爭態勢

概述
各公司市場排名
主要進展
公司地理分佈
公司產業足跡
ACE矩陣

第10章公司簡介

GE Healthcare
Curium Pharma
Novartis
Cardinal Health
Lantheus Medical Imaging
Jubilant Life Sciences Ltd
Nordion Inc.
Bracco Imaging SPA
The Institute for Radioelements（IRE）
NTP Radioisotopes SOC Ltd.

第10章已驗證的市場情報

關於已驗證的市場情報
動態資料視覺化

簡介目錄

Product Code: 38092

Nuclear Medicine Market Valuation - 2026-2032

The increasing prevalence of chronic diseases such as cardiovascular diseases, cancer, respiratory disorders, neurological disorders, and metabolic conditions is a significant driver for the nuclear medicine market. Thus, the rising prevalence of chronic disorders surged the growth of market size surpassing USD 6.8 Billion in 2024 to reach a valuation of USD 12.99 Billion by 2032.

The adoption of nuclear medicine in the healthcare sector was at a nascent stage compared to traditional drug products. However, advancements in medical imaging technologies, radiopharmaceuticals, and the growing understanding of nuclear medicine's benefits have led to its increasing adoption. Thus, the increasing adoption of nuclear medicine in the healthcare sector enables the market to grow at a CAGR of 9.30% from 2026 to 2032.

Nuclear Medicine Market: Definition/ Overview

Nuclear medicine is a multidisciplinary field that utilizes radioactive materials, or radiopharmaceuticals, for the diagnosis and treatment of various diseases in areas such as neurology, cardiology, the endocrine system, the gastrointestinal system, and cancers. Radiopharmaceuticals contain a radioactive tracer that, when injected into the patient's body, emits gamma rays. These rays are captured by advanced imaging techniques like Single-Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET), enabling highly detailed images that aid in early detection, accurate diagnosis, and comprehensive examination of diseases, surpassing the capabilities of conventional imaging methods.

Recent advancements in radiopharmaceuticals have enhanced the ability to study micro-level physiological processes, such as cancer cell proliferation, myocardial perfusion in cardiac conditions, ventilation in severe pneumonia cases, and thyroid and parathyroid activity in hyperthyroidism. Nuclear medicine is increasingly used in research and development for next-generation therapies, including radiopharmaceutical conjugates with antibodies, biological drugs, and peptides. This enables targeted drug delivery, dose optimization, and the creation of innovative therapeutic solutions. As a result, nuclear medicine is not only a powerful diagnostic tool but also a key player in advancing therapeutic strategies across multiple medical fields.

How Does the Rising Incidence of Cancer and Cardiovascular Diseases Surge the Growth of the Nuclear Medicine Market?

According to the World Health Organization (WHO), cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. The American Heart Association reported that cardiovascular disease is the leading global cause of death, accounting for more than 17.9 million deaths per year in 2019. Technological advancements in radiopharmaceuticals and imaging equipment. According to the Verified Market Research, the Radiopharmaceuticals Market was valued at 6.05 billion in 2023 and is projected to reach USD 13.61 Billion by 2032, growing CAGR of 11.76%.

Increasing investment in nuclear medicine research and development. The U.S. Department of Energy's Office of Science budget for Nuclear Physics research was $713 million in fiscal year 2021. The European Commission allocated €1.38 billion for nuclear research and training activities under the Euratom Research and Training Programme 2021-2025. Growing awareness and acceptance of personalized medicine. According to the report of Verified Market Research the Personalized Medicine Market was valued at 130.23 Billion in 2023 and is projected to grow at 272.59 Billion by 2032, growing CAGR 10.67% from 2026 to 2032. A survey by the Personalized Medicine Coalition found that 73% of oncologists use personalized medicine testing for cancer patients.

Expanding applications of radioisotopes in molecular imaging. The U.S. Nuclear Regulatory Commission reported that approximately 50 million nuclear medicine procedures are performed each year in the United States. Increasing geriatric population and associated chronic diseases. The United Nations reported that the global population aged 65 and over is growing faster than all other age groups, expected to double to 1.5 billion by 2050. The WHO projects that by 2030, 1 in 6 people in the world will be aged 60 years or over, increasing the demand for diagnostic and therapeutic nuclear medicine procedures.

How does the High Cost of Nuclear Medicine Procedures and Equipment Impede the Growth of the Nuclear Medicine Market?

The high cost of nuclear medicine procedures and equipment hinders the growth of the nuclear medicine market. According to the American College of Radiology, the average cost of a PET/CT scan in the U.S. ranges from $1,250 to $1,650, which is prohibitively expensive for many patients. Stringent regulatory requirements. The U.S. Nuclear Regulatory Commission reported that it takes an average of 24 months to review and approve a new radiopharmaceutical. In Europe, the European Medicines Agency (EMA) approved only 3 new radiopharmaceuticals between 2018 and 2022, highlighting the rigorous approval process.

Short half-life of radiopharmaceuticals. The Society of Nuclear Medicine and Molecular Imaging noted that commonly used radioisotopes like Technetium-99m have a half-life of only 6 hours, complicating logistics and increasing costs. A study in the Journal of Nuclear Medicine found that up to 20% of prepared doses of short-lived radiopharmaceuticals go unused due to logistical challenges. Shortage of skilled nuclear medicine technologists. The U.S. Bureau of Labor Statistics projected a 5% growth in demand for nuclear medicine technologists from 2019 to 2029 but noted that the field is small, with only about 18,000 jobs in 2019. A survey by the American Society of Radiologic Technologists found that 4.7% of nuclear medicine technologist positions were vacant in 2019, indicating a shortage of qualified professionals.

Category-Wise Acumens

How the Diagnostic Imaging Technologies Foster the Growth of Diagnostic Nuclear Medicine Segment?

The diagnostic nuclear medicine segment dominates in the nuclear medicine market driven by advancements in diagnostic imaging technologies, such as the ability to capture high-resolution 3D images, faster device processing speeds, and increased automation. These improvements enhance the accuracy and efficiency of diagnosing various diseases, making nuclear medicine an essential tool in modern healthcare. Additionally, government interventions and the approval of numerous nuclear medicines for different disease treatments have accelerated the commercialization of these products, further expanding the segment's reach.

The development of a robust supply chain for radiopharmaceuticals and the availability of advanced infrastructure for the production and distribution of these medicines are also contributing to the segment's dominance. As a result, nuclear medicine is becoming more accessible, allowing healthcare providers to utilize cutting-edge diagnostic tools for early detection and precise treatment planning. These factors, coupled with growing healthcare investments and the demand for better diagnostic solutions, are expected to drive the market forward. The diagnostic nuclear medicine segment will continue to play a critical role in the healthcare landscape, improving patient outcomes and shaping the future of medical imaging and treatment.

How the Increasing Prevalence of Cancer Surge the Growth of Oncology Segment?

The oncology segment is set to dominate nuclear medicine driven by the increasing global burden of cancer. Changes in lifestyle, including unhealthy diets, smoking, and sedentary work habits, have significantly contributed to the rising incidence of cancer. Rapid urbanization has led to a larger population engaging in regular smoking, which remains a leading risk factor for various types of cancer. Additionally, sedentary lifestyles, characterized by minimal physical activity and a higher intake of processed and junk food, further exacerbate the cancer risk.

With cancer continuing to cause a significant number of deaths worldwide, there is a growing demand for more effective diagnostic and therapeutic tools. Nuclear medicine plays a critical role in oncology by offering highly advanced imaging techniques for early detection and precise diagnosis, which are crucial for improving treatment outcomes. Moreover, there has been a surge in investments aimed at developing novel radiopharmaceuticals and therapies specifically designed for cancer treatment. These advancements enable targeted treatment, improving patient outcomes while minimizing side effects.

Country/Region-wise Acumens

How Does the High Prevalence of Cancer and Cardiovascular Diseases Surge the Growth of the Nuclear Medicine Market in North America?

The increasing prevalence of cancer and cardiovascular disorders escalates the growth of nuclear medicine. According to the American Cancer Society, an estimated 1.9 million new cancer cases were diagnosed in the United States in 2021. The Centers for Disease Control and Prevention (CDC) reported that heart disease remains the leading cause of death in the U.S., accounting for about 659,000 deaths annually as of 2020. Strong research and development infrastructure The National Institutes of Health (NIH) budget for cancer research reached USD 6.56 Billion in fiscal year 2021, a significant portion of which supports nuclear medicine research. The Society of Nuclear Medicine and Molecular Imaging (SNMMI) reported that over 20 million nuclear medicine procedures are performed each year in the United States.

Favorable Reimbursement Policies and Healthcare Spending. the Centers for Medicare & Medicaid Services (CMS) reported that national health spending in the U.S. grew 9.7% to $4.1 trillion in 2020, or $12,530 per person. A study published in the Journal of Nuclear Medicine found that Medicare reimbursement for PET scans increased by 14% between 2017 and 2020, encouraging wider adoption.

How does the Rapid Growth in Healthcare Infrastructure and Spending Foster the Growth of the Nuclear Medicine Market in Asia Pacific?

The growing healthcare infrastructure and high investment surge the growth of the nuclear medicine market in the Asia Pacific. According to the World Health Organization, healthcare spending in the Asia Pacific region was projected to grow at an annual rate of 7.1% between 2020 and 2024, outpacing the global average of 5.4%. China's healthcare expenditure reached 7.12 trillion yuan (approximately USD 1.1 Trillion) in 2020, a 10.2% increase from the previous year, as reported by the National Health Commission of China.

Increasing prevalence of cancer and cardiovascular diseases. The International Agency for Research on Cancer (IARC) estimated that in 2020, there were approximately 8.9 million new cancer cases in Asia, accounting for nearly half of the global cancer burden. The Asian Pacific Society of Cardiology reported that cardiovascular diseases accounted for 35% of all deaths in the Asia Pacific region in 2019, highlighting the need for advanced diagnostic and therapeutic options. Growing adoption of nuclear medicine technologies. The Indian nuclear medicine market was expected to grow at a CAGR of 10.5% between 2021 and 2026, driven by increasing government initiatives and rising awareness, as per a study published in the Journal of Nuclear Medicine Technology.

Competitive Landscape

The competitive landscape of the Nuclear Medicine Market is characterized by technological innovation, regulatory compliance, and a focus on providing high-quality, cost-effective services. Players must continuously invest in research and development, build strong partnerships, and adapt to evolving market trends to maintain a competitive edge.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the nuclear medicine market include:

Lantheus Medical Imaging, Inc.
Cardinal Health
Norgine B.V.
Nordion, Inc.
Bayer AG
Curium
Advanced Accelerator Applications
Bracco Diagnostic, Inc.
Jubilant Pharmova Limited
GE Healthcare (General Electric Company)

Latest Developments:

In April 2024, Curium announced the acquisition of EczacIbasI-Monrol Nuclear Product Co. This acquisition is expected to broaden its geographical reach, PET and SPECT infrastructure, and enable the development of cutting-edge radionuclide and radiopharmaceutical pipelines for diagnostic and therapeutic applications.
In February 2024, Curium reported that the Swissmedic had accepted their marketing authorization application for PYLCLARI, a novel (18F)-PSMA PET tracer, for evaluation.
In February 2024, Lantheus Holdings, Inc. announced the collaboration with the Consortium for Clarity in Alzheimer's Disease Research via Imaging (CLARiTI), which was financed by the National Institute on Aging.

1 INTRODUCTION OF THE GLOBAL NUCLEAR MEDICINE MARKET

1.1 Market Definition
1.2 Market Segmentation
1.3 Research Timelines
1.4 Assumptions
1.5 Limitations

2 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

2.1 Data Mining
2.2 Data Triangulation
2.3 Bottom-Up Approach
2.4 Top-Down Approach
2.5 Research Flow
2.6 Key Insights from Industry Experts
2.7 Data Sources

3 EXECUTIVE SUMMARY

3.1 Market Overview
3.2 Ecology Mapping
3.3 Absolute Market Opportunity
3.4 Market Attractiveness
3.5 Global Nuclear Medicine Market Geographical Analysis (CAGR %)
3.6 Global Nuclear Medicine Market, By Type (USD Million)
3.7 Global Nuclear Medicine Market, By Application (USD Million)
3.8 Global Nuclear Medicine Market, By End-Users(USD Million)
3.9 Future Market Opportunities
3.10 Global Market Split
3.11 Product Life Line

4 GLOBAL NUCLEAR MEDICINE MARKET OUTLOOK

4.1 Global Nuclear Medicine Evolution
4.2 Drivers
- 4.2.1 Driver1
- 4.2.2 Driver 2
4.3 Restraints
- 4.3.1 Restraint1
- 4.3.2 Restraint 2
4.4 Opportunities
- 4.4.1 Opportunity1
- 4.4.2 Opportunity 2
4.5 Porters Five Force Model
4.6 Value Chain Analysis
4.7 Pricing Analysis
4.8 Macroeconomic Analysis

5 GLOBAL NUCLEAR MEDICINE MARKET BY TYPE

5.1 Overview
5.2 Diagnostic Nuclear Medicine
5.3 PET Radiopharmaceuticals
5.4 SPECT Radiopharmaceuticals
5.5 Therapeutic Nuclear Medicine

6 GLOBAL NUCLEAR MEDICINE MARKET BY APPLICATION

6.1 Overview
6.2 Oncology
6.3 Neurology
6.4 Cardiology

7 GLOBAL NUCLEAR MEDICINE MARKET, BY END-USERS

7.1 Overview
7.2 Hospitals & Clinics
7.3 Diagnostic Centers

8 GLOBAL NUCLEAR MEDICINE MARKET BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Spain
- 8.3.6 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Argentina
- 8.5.3 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 UAE
- 8.6.2 Saudi Arabia
- 8.6.3 South Africa
- 8.6.4 Rest of Middle-East and Africa

9 GLOBAL NUCLEAR MEDICINE MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Developments
9.4 Company Regional Footprint
9.5 Company Industry Footprint
9.6 ACE Matrix

10 COMPANY PROFILES

10.1 GE Healthcare
- 10.1.1 Company Overview
- 10.1.2 Company Insights
- 10.1.3 Product Benchmarking
- 10.1.4 Key Developments
- 10.1.5 Winning Imperatives
- 10.1.6 Current Focus & Strategies
- 10.1.7 Threat from Competition
- 10.1.8 SWOT Analysis
10.2 Curium Pharma
- 10.2.1 Company Overview
- 10.2.2 Company Insights
- 10.2.3 Product Benchmarking
- 10.2.4 Key Developments
- 10.2.5 Winning Imperatives
- 10.2.6 Current Focus & Strategies
- 10.2.7 Threat from Competition
- 10.2.8 SWOT Analysis
10.3 Novartis
- 10.3.1 Company Overview
- 10.3.2 Company Insights
- 10.3.3 Product Benchmarking
- 10.3.4 Key Developments
- 10.3.5 Winning Imperatives
- 10.3.6 Current Focus & Strategies
- 10.3.7 Threat from Competition
- 10.3.8 SWOT Analysis
10.4 Cardinal Health
- 10.4.1 Company Overview
- 10.4.2 Company Insights
- 10.4.3 Product Benchmarking
- 10.4.4 Key Developments
- 10.4.5 Winning Imperatives
- 10.4.6 Current Focus & Strategies
- 10.4.7 Threat from Competition
- 10.4.8 SWOT Analysis
10.5 Lantheus Medical Imaging
- 10.5.1 Company Overview
- 10.5.2 Company Insights
- 10.5.3 Product Benchmarking
- 10.5.4 Key Developments
- 10.5.5 Winning Imperatives
- 10.5.6 Current Focus & Strategies
- 10.5.7 Threat from Competition
- 10.5.8 SWOT Analysis
10.6 Jubilant Life Sciences Ltd
- 10.6.1 Company Overview
- 10.6.2 Company Insights
- 10.6.3 Product Benchmarking
- 10.6.4 Key Developments
- 10.6.5 Winning Imperatives
- 10.6.6 Current Focus & Strategies
- 10.6.7 Threat from Competition
- 10.6.8 SWOT Analysis
10.7 Nordion Inc.
- 10.7.1 Company Overview
- 10.7.2 Company Insights
- 10.7.3 Product Benchmarking
- 10.7.4 Key Developments
- 10.7.5 Winning Imperatives
- 10.7.6 Current Focus & Strategies
- 10.7.7 Threat from Competition
- 10.7.8 SWOT Analysis
10.8 Bracco Imaging S.P.A
- 10.8.1 Company Overview
- 10.8.2 Company Insights
- 10.8.3 Product Benchmarking
- 10.8.4 Key Developments
- 10.8.5 Winning Imperatives
- 10.8.6 Current Focus & Strategies
- 10.8.7 Threat from Competition
- 10.8.8 SWOT Analysis
10.9 The Institute for Radioelements (IRE)
- 10.9.1 Company Overview
- 10.9.2 Company Insights
- 10.9.3 Product Benchmarking
- 10.9.4 Key Developments
- 10.9.5 Winning Imperatives
- 10.9.6 Current Focus & Strategies
- 10.9.7 Threat from Competition
- 10.9.8 SWOT Analysis
10.10 NTP Radioisotopes SOC Ltd.
- 10.10.1 Company Overview
- 10.10.2 Company Insights
- 10.10.3 Product Benchmarking
- 10.10.4 Key Developments
- 10.10.5 Winning Imperatives
- 10.10.6 Current Focus & Strategies
- 10.10.7 Threat from Competition
- 10.10.8 SWOT Analysis